Clinical trials: Myeloma, Plasma-Cell
Multiple Myeloma
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®)…
- Trial name
- BiRd vs Rd (NCT02516696)
- Testing
- Clarithromycin, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed and/or Refractory Multiple Myeloma
Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma
The purpose of this study is to determine safety of P276-00 in patients with advanced multiple myeloma and whether P276-00 is effective in the treatment of advanced cases of multiple myeloma.
- Trial name
- NCT00882063
- Testing
- P276-00
- Where
- 5 sites in India
- Volunteers
- 19 people
- Sponsor
- Piramal Enterprises Limited
Multiple Myeloma
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
This study employs a prospective, multicenter, randomized, two-arm design aimed at evaluating the efficacy and safety of the FTO regimen in preventing delayed chemotherapy-induced nausea and vomiting (CINV) following high-dose…
- Trial name
- NCT07413809
- Testing
- Fosaprepitant, Tropisetron, Olanzapine
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Multiple Myeloma, Multiple Myeloma in Relapse
TriPRIL CAR T Cells in Multiple Myeloma
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells.
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
- Trial name
- NCT05020444
- Testing
- TriPRIL CAR T Cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Ovarian Cancer, Renal Cancer
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
The primary objectives of this Phase 1b/2 study were as follows: Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed solid tumors and in patients with relapsed and/or…
- Conditions
- Ovarian Cancer, Renal Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT00531284
- Testing
- Carfilzomib, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 184 people
- Sponsor
- Amgen
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
This phase I/II trial studies whether stopping cyclosporine before mycophenolate mofetil is better at reducing the risk of life-threatening graft-versus-host disease (GVHD) than the previous approach where mycophenolate mofetil…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00078858
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 37 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
The purpose of this study is to test the safety and efficacy of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients with Relapsed or Refractory Multiple Myeloma.
- Trial name
- APRIL (NCT03287804)
- Testing
- AUTO2
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Autolus Limited
Covid19, Myeloma Multiple
Impact of COVID-19 After Autologous Hematopoietic Stem Cell Transplantation in Sweden
This retrospective observational cohort study aims to describe the impact of COVID-19 in patients treated with autologous stem cell transplantation (ASCT) for malignant disease in terms of risk factors, morbidity, need for…
- Conditions
- Covid19, Myeloma Multiple, Malignant Lymphoma, Hematologic Neoplasms
- Trial name
- AutoCOVID-19 (NCT04760184)
- Testing
- Autologous stem cell transplantation
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Uppsala University
Neoplasm
Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts
Most bone marrow transplantations for malignant and non-malignant disease include whole body irradiation. Techniques for administering that treatment, including patient positioning, lung and soft tissue compensation, dose rate…
- Trial name
- NCT00026858
- Testing
- collaboration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
This study will assess the safety, pharmacokinetic (PK), pharmacodynamic (PD) and the therapeutic potential of GSK2857916 in subjects with multiple myeloma (MM) and lymphomas that express B cell maturation antigen (BCMA).
- Trial name
- NCT02064387
- Testing
- GSK2857916
- Where
- 9 sites in United States, Canada and 1 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of relapsed or refractory multiple myeloma subjects
- Trial name
- NCT05913804
- Testing
- YTS104 Cells injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This phase II trial is studying the side effects and best dose of alemtuzumab when given together with fludarabine phosphate and total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients who…
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Trial name
- NCT00118352
- Testing
- alemtuzumab, total-body irradiation, fludarabine phosphate
- Where
- 2 sites in United States, Italy
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma
The purpose of the study is to determine the safety and efficacy of the use of bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma.
- Trial name
- BVRD (NCT01484626)
- Testing
- Bendamustine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Loyola University
Multiple Myeloma, Refractory Multiple Myeloma
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Trial name
- NCT06348108
- Testing
- Talquetamab, Iberdomide, Dexamethasone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Alfred Chung, MD
Metastatic Cancer, Cancer, Breast
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Sarcopenia is defined as reduction in muscle mass and function according to the criteria of the European Working Group on Sarcopenia in older people.
- Conditions
- Metastatic Cancer, Cancer, Breast, Cancer Colon, Cancer, Rectum
- Trial name
- SPACE2 (NCT05154474)
- Testing
- Standard
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Weprom
Multiple Myeloma
Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse
Assessment of the antitumour effect of zoledronic acid in patients with multiple myeloma and asymptomatic biochemical relapse It´s proposed to investigate the use of Zoledronic acid as single therapy in patients with Multiple…
- Trial name
- AZABACHE (NCT01087008)
- Testing
- zoledronic acid, No treatment control
- Where
- 16 sites in Spain
- Volunteers
- 103 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma, Myeloma, Plasma-Cell
Phase I/II Study of hLL1 in Multiple Myeloma
This is a Phase I/II, open-label, multi-center study conducted in patients with recurrent or refractory multiple myeloma who have failed at least two prior standard systemic treatments.
- Conditions
- Multiple Myeloma, Myeloma, Plasma-Cell, PLASMACYTOMA
- Trial name
- NCT00421525
- Testing
- milatuzumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Multiple Myeloma
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
The current study is being conducted to evaluate the possibility that a different schedule of bortezomib, doxorubicin HCl liposome, and dexamethasone might decrease the incidence of peripheral neuropathy yet maintain similar…
- Trial name
- NCT00366106
- Testing
- bortezomib, dexamethasone, doxorubicin HCl liposome
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Accelerated Community Oncology Research Network
Waldenstrom's Macroglobulinemia
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Rituximab is a monoclonal antibody with proven efficacy in WM but responses are slow. Bortezomib has shown significant and rapid activity in WM.
- Trial name
- NCT01046006
- Testing
- Bortezomib, Rituximab, Dexamethasone
- Where
- 4 sites in Greece, Netherlands and 1 more
- Volunteers
- 59 people
- Sponsor
- Meletios A. Dimopoulos
Multiple Myeloma
Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
The objective of this study is to evaluate the efficacy and safety of Velcade plus dexamethasone used as induction chemotherapy prior to autologous transplantation.
- Trial name
- NCT00337506
- Testing
- Dexamethasone, velcade
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.